Publications by authors named "G Osorio-Gomez"
Article Synopsis
- - Biological therapy, specifically brodalumab, shows promise in treating hidradenitis suppurativa (HS) by targeting the IL-17 receptor, which may play a role in the disorder's immune dysregulation.
- - A study involving 16 adults with moderate to severe HS found that 50% achieved an improvement in symptoms and experienced a significant decrease in disease severity after 16 weeks of brodalumab treatment.
- - The treatment was generally safe, with some patients experiencing mild adverse effects, suggesting that brodalumab is a viable option for those who did not respond to previous biologics like adalimumab.
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.
Pablo Fernandez-Crehuet Sofía Haselgruber Alicia Padial-Gomez Fiorella Vasquez-Chinchay Maria Dolores Fernandez-Ballesteros
Dermatol Ther (Heidelb)
April 2023
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin condition, and secukinumab, a biologic drug, is being studied for its effectiveness and safety in treating moderate to severe cases over 16 weeks.
- A study involving 47 patients in southern Spain found that nearly 49% achieved significant clinical improvement (HiSCR) after treatment, with only a small percentage experiencing adverse effects.
- Factors such as being female, having a lower body mass index (BMI), and a lower previous treatment burden were linked to a higher likelihood of achieving the desired treatment response.
Down syndrome (DS) has been related to a higher risk of hidradenitis suppurativa (HS). This cross-sectional study assessed DS patients with HS in a Spanish single-centre sample. DS participants presented a lower age of onset, age at diagnosis and time to diagnosis.
View Article and Find Full Text PDF